Astria Therapeutics, a Boston-based biopharmaceutical company, has announced a global exclusive license agreement with Ichnos Sciences. The agreement involves the development of an OX40 portfolio for the potential treatment of atopic dermatitis (AD) and other allergic and immunological diseases.
Focus on Lead Candidate: STAR-0310
Astria Therapeutics will focus on the lead candidate from the portfolio, STAR-0310, for the treatment of AD. The company aims to submit an investigational new drug application for STAR-0310 by the end of 2024.
Financial Aspects
As part of the agreement, Astria will pay Ichnos a license fee of $15 million upfront. Additionally, there is potential for up to $305 million in payments based on specific development milestones. Ichnos may also receive tiered royalties depending on the annual net sales of any resulting licensed products.
Clinical Trial Plans
Subject to IND approval, Astria plans to initiate a Phase 1a clinical trial in the first quarter of 2025. The company expects to receive results from the trial in the third quarter of the same year.
Preclinical-stage Program: STAR-0310
Currently, STAR-0310 is in the preclinical stage of development.
